医学临床研究
  2025年7月26日 星期六           首 页    |    期刊简介    |    编委会    |    投稿指南    |    期刊订阅    |    广告合作    |    留言板    |    联系我们    |    English
医学临床研究  2020, Vol. 37 Issue (9): 1340-1342    DOI: 10.3969/j.issn.1671-7171.2020.09.019
  论著 本期目录 | 过刊浏览 | 高级检索 |
奥氮平与利培酮对精神分裂症患者血清BDNF、NGF、IL-6水平的影响及临床应用效果比较
朱淼, 尹岸民, 张东良
淮安市第三人民医院精神九科,江苏 淮安 223001
Effects of Olanzapine and Risperidone on Serum Levels of BDNF, NGF and IL-6 in Patients with Schizophrenia
ZHU Miao, YIN An-min, ZHANG Dong-liang
Department of Psychiatry,the Third People's Hospital of Huai'an City,Jiangsu Province, 223001
全文: PDF (0 KB)   HTML (0 KB) 
输出: BibTeX | EndNote (RIS)      
摘要 【目的】 比较奥氮平与利培酮对精神分裂症患者血清脑源性神经营养因子(BDNF)、神经生长因子(NGF)、白介素-6(IL-6)水平的影响及临床应用效果。【方法】 前瞻性选取2018年3月至2020年6月本院收治的72例精神分裂症患者为研究对象,采用随机数表法将其分为利培酮组与奥氮平组,每组各36例。分别给予利培酮、奥氮平治疗,持续6个月。比较两组患者干预前后血清BDNF、NGF、IL-6水平,并比较阳性阴性症状量表(PANSS)评分以及不良反应发生率。【结果】 治疗1、3、6个月,两组患者PANSS评分均显著低于治疗前,差异有统计学意义(P<0.05);治疗6个月,奥氮平组PANSS评分显著高于利培酮组,差异有统计学意义(P<0.05)。治疗1、3、6个月,两组患者血清BDNF、NGF水平高于治疗前,血清IL-6水平低于治疗前,差异有统计学意义(P<0.05)。治疗3、6个月,奥氮平组血清BDNF水平显著高于利培酮组,治疗6个月时血清NGF水平高于利培酮组,血清IL-6水平低于利培酮组,差异均有统计学意义(均P<0.05)。奥氮平组患者锥体外系的发生率显著低于利培酮组,差异有统计学意义(P<0.05)。【结论】 奥氮平能显著降低精神分裂症患者的血清BDNF、NGF、L-6水平,可较好缓解患者的精神分裂症状,长期应用效果优于利培酮,且安全性更高。
服务
把本文推荐给朋友
加入我的书架
加入引用管理器
E-mail Alert
RSS
作者相关文章
朱淼
尹岸民
张东良
关键词 精神分裂症脑源性神经营养因子/血液神经生长因子/血液    
Abstract【Objective】 To compare the effect of olanzapine and risperidone on serum brain derived neurotrophic factor (BDNF), nerve growth factor (NGF), interleukin-6 (IL-6) levels and clinical application effect in patients with schizophrenia. 【Methods】 Seventy-two patients with schizophrenics admitted to our hospital from March 2016 to September 2018 were enrolled for the study and randomly divided into risperidone group (n=36) and olanzapine group (n=36), and they were treated with risperidone and olanzapine respectively for 6 months. The serum levels of BDNF, NGF, IL-6, the score of positive and negative symptom scale (PANSS) and the incidence of adverse reactions were compared before and after intervention between two groups. 【Results】 There were no significant differences in baseline data, total score of PANSS, serum levels of BDNF, NGF and IL-6 between two groups (P>0.05). For intra-comparison, the PANSS total score and serum level of IL-6 at 1, 3, 6 months after intervention in two groups were significantly lower than that before intervention, and serum levels of BDNF and NGF at 1, 3, 6 months after intervention were significantly higher than that before intervention (P<0.05). For inter-comparison, the PANSS total score and serum level of NGF at 6 months after intervention in olanzapine group were significantly higher than that in the risperidone group at the same time, the serum level of BDNF at 3 and 6 months after intervention in the olanzapine group was significantly higher than that of the risperidone group at the same time, and the serum level of IL-6 at 6 months after intervention in the olanzapine group was significantly lower than that in the risperidone group at the same time (P<0.05). The incidence of extrapyramidal system in the olanzapine group was significantly lower than that in the risperidone group (P<0.05), and there were no significant differences in other adverse reactions including headache, dizziness, abnormal sleep, increased body mass and dry mouth between two groups (P>0.05). 【Conclusion】 Olanzapine can significantly reduce the serum levels of BDNF, NGF and L-6 in schizophrenic patients. Olanzapine can better alleviate the symptoms of schizophrenia. The long-term effect of olanzapine is better than risperidone, and the safety is higher.
Key wordsSchizophrenia    Brain-Derived Neurotrophic Factor/BL    Nerve Growth Factor/BL
收稿日期: 2020-06-15     
PACS:  R749.3  
引用本文:   
朱淼, 尹岸民, 张东良. 奥氮平与利培酮对精神分裂症患者血清BDNF、NGF、IL-6水平的影响及临床应用效果比较[J]. 医学临床研究, 2020, 37(9): 1340-1342.
ZHU Miao, YIN An-min, ZHANG Dong-liang. Effects of Olanzapine and Risperidone on Serum Levels of BDNF, NGF and IL-6 in Patients with Schizophrenia. JOURNAL OF CLINICAL RESEARCH, 2020, 37(9): 1340-1342.
链接本文:  
http://journal07.magtech.org.cn/yxlcyj/CN/10.3969/j.issn.1671-7171.2020.09.019     或     http://journal07.magtech.org.cn/yxlcyj/CN/Y2020/V37/I9/1340
版权所有 © 2013 医学临床研究杂志社  湘ICP备13012052号-1
办公地址:湖南省长沙市芙蓉区新军路43号煤炭大院主办公楼6楼621、623、632、636室 邮编:410011 电话(传真):0731-84824007 E-mail:jcr_cs.hn@vip.163.com
技术支持:北京玛格泰克科技发展有限公司 技术支持:support@magtech.com.cn